FDA Investigator Kassa Ayalew, MD
Kassa Ayalew, MD has conducted inspections on 8 sites in 6 countries as of 02 Sep 2019. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
8
Last Inspection Date:
02 Sep 2019
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
Brazil,
United States of America,
Argentina,
India,
France,
Spain
FDA Investigators that have inspected at least one site in common with Kassa Ayalew, MD:
Adam R Cooke,
Allen Lou,
Angela Shepas,
Barbara M Frazier,
Betsy C Galliher,
Bonita S Chester,
Byungja E Marciante,
CDR Thomas R Berry, PPh,
Charles J Chacko,
Cheryl A Grandinetti,
Christina N Maurino,
Cynthia F Kleppinger, MD,
Deborah B Nixon,
Denise M Visco, Investigator,
Devaughn Edwards,
Douglas C Kovacs,
Eileen J Bannerman,
Emmanuel Jramos Maldonado,
Eric Rothschild,
Erin D Mccaffery,
Ethan P Stegman,
Gene R Gunn,
George Pyramides,
Guerlain Ulysse,
Jawaid Hamid,
Jean M Kelahan,
Joan A Loreng,
Joseph F Owens,
Karen E D'orazio,
Lata C Mathew, PhD,
Leon L Crawley,
Liatte Kreuger, PharmD,
Lisa Harlan,
Marcia A Worley,
Matthew A Spataro,
Mayar M Mussa,
Melissa T Roy,
Michael F Skelly, PhD,
Michael Serrano,
Michelle D Haamid,
Nicole M Bell,
Nina Yang,
Paul L Bellamy,
Peter R Lenahan,
Randy L Clarida,
Rebecca T Davis,
Regina T Brown,
Robert Jennings,
Rodney T Allnutt,
Seneca D Toms,
Sereen Gmorgan Murray,
Sheri S Oliver,
Sonya M Edmonds,
Stephanie T Durso,
Susan D Yuscius,
Tara K Carmody,
Tonia F Bernard,
Tracy R Ball,
Tyanna N Hadley,
Vanessa E Coulter,
Viviana Matta,
William P Tonkins,
Yvesna C Blaise
Kassa Ayalew, MD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| April, 2015 | EIR | GlaxoSmithKline - EIR, 2015-04-10 |
| December, 2018 | FDA 483 Response | Novartis Pharmaceuticals Corporation - Form 483R, 2019-01-21 |
| August, 2019 | FDA 483 | PPD, Inc., part of Thermo Fisher Scientific - Form 483, 2019-08-15 |
| January, 2018 | FDA 483 | Conrado Estol, M.D. - Form 483, 2018-01-12 |
| December, 2018 | FDA 483 | Novartis Pharmaceuticals Corporation - Form 483, 2018-12-14 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more